Navigation Links
Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms
Date:8/21/2014

BURLINGTON, Mass., Aug. 21, 2014 /PRNewswire/ -- Decision Resources Group finds that, for the treatment of COPD,  physicians in Brazil and Mexico manage to follow clinical guidelines and commonly prescribe long-acting beta-agonist (LABA)- and long-acting muscarinic antagonist (LAMA)- containing regimens, although they do so within current severe cost/coverage constraints. Therefore, new brands of LABA/LAMA fixed-dose combinations (FDCs) that are expected to launch in these countries—which will considerably expand the chronic obstructive pulmonary disease (COPD) market—will compete with well-established marketed therapies, especially the twice-daily LABA/ inhaled corticosteroids (ICS) FDCs. New LABA/LAMA FDCs will also compete with recently launched once-daily Relvar/Relvare (GlaxoSmithKline/Theravance). According to payers, improvements in dosing and delivery of new FDCs of current drugs/drug classes are important but may not be enough to justify a premium price over comparator drugs or its separate components.

Other key findings from the Emerging Markets Physician and Payer Forum report entitled Positioning of Current and Emerging Agents for COPD: Physician and Payer Perspectives on the Prescribing and Patient Access Landscape in Brazil and Mexico include:

  • Factors impacting formulary inclusion: In Brazil, CONITEC (Brazil's HTA agency) is restricting the incorporation of new COPD drugs in the coverage offered by the public healthcare system. Demonstration of superior comparative clinical and economic benefit, preferably using local data, is crucial to formulary inclusion.
  • Exclusion of key agents: In Mexico, although the national drug formulary lists a comprehensive range of COPD drugs that can be covered by government-sponsored or Social Security programs, individual institutions have been excluding some key agents based on their own budgets.
  • Private patients' access to treatment: The budgetary environment seems less restrictive in the private sector than in the public sector, but the lack of coverage in the outpatient setting in Brazil and of mandatory coverage in Mexico—together with expensive out-of-pocket costs in both countries—is limiting some eligible COPD private patients' access to treatment.

Comments from Decision Resources Group Director Andreia Ribeiro, Ph.D.:

  • "Upon the launch of generic LABA/ICS FDCs (GlaxoSmithKline's Seretide and AstraZeneca's Symbicort) and LAMAs (Boehringer Ingelheim's Spiriva), their use is likely to be promoted, due to the tendering purchase models used in the public sector in both countries. COPD patients in Brazil and Mexico are already requesting currently available low-priced generics, according to our survey findings." 
  • "Particularly in Brazil, state coverage and judicial actions are a powerful driver of access to costly agents, especially those not included in the formularies. Also, in some cases, patient assistance programs are the only way for patients to access drugs not covered under a specific public sector scheme, as in the case of Seguro Popular in Mexico. Manufacturers should explore these opportunities to best position their drugs in these markets."

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresourcesgroup.com

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO


'/>"/>
SOURCE Decision Resources Group
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema
2. Globavir Seeking Approval and Launch of Novel Ebola Treatment Before Year End
3. The Impact of Genericization in the Unipolar Depression Market Will be Tempered by the Continued Uptake of Novel Antidepressants and Antipsychotics
4. Charleston Laboratories and Daiichi Sankyo Announce Collaboration to Develop and Commercialize Novel, Fixed-Dose Combination Hydrocodone Products for Pain and Opioid-Induced Nausea and Vomiting (OINV) in the US
5. FDA Grants Fast Track Designation to CTI BioPharmas Pacritinib, a Novel JAK2 Inhibitor for the Treatment of Myelofibrosis
6. Daiichi Sankyo and Charleston Laboratories Announce Collaboration to Develop and Commercialize Novel, Fixed-Dose Combination Hydrocodone Products for Pain and Opioid-Induced Nausea and Vomiting (OINV) in the US
7. Glide Pharma Takes Exclusive Worldwide Rights to Novel Diagnostic Technology for Prostate Cancer
8. Particle Sciences and Eyeon Therapeutics Receive Patent on Novel Dry Eye Technology
9. Glide Pharma Completes Successful Proof-of-Concept Study with Novel Solid Dose Formulation of Octreotide
10. Synthetic Biologics Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treating Whooping Cough (Pertussis) at Gordon Research Conference
11. ViaCyte Files Investigational New Drug Application and Device Master File with FDA for Novel Cell Replacement Therapy Product Candidate Designed to Treat Patients with Type 1 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Medical, Inc. (Nasdaq: AEMD ), the pioneer ... diseases, today announced results for the third quarter ... --> --> "Beyond ... quarterly call, we strategically advanced pre-clinical and clinical ... the Aethlon Hemopurifier® as a leading broad-spectrum countermeasure ...
(Date:2/4/2016)... N.Y. , Feb. 4, 2016  AMRI (NASDAQ:  AMRI) ... President of Pfizer Inc. and President of Pfizer Global Supply, ... as of February 4, 2016. In addition, the Company announced ... of the audit committee since 2010, has retired from the ... and attention to his other business ventures.  ...
(Date:2/4/2016)... PUNE, India , February 4, 2016 ... to the new Market Research Report "North American Automated ... and Fully-Automated External Defibrillators), by End-User (Public Facilities, Hospitals, ... North American automated external defibrillators (AED) report defines and ... of the revenue. This market is estimated to grow ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... February 06, 2016 , ... ... MEDIA ADVISORY: 5000 PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO ... in the world with an estimated 5000 perioperative nurses in attendance to ...
(Date:2/5/2016)... ... February 05, 2016 , ... Steven Tonkinson, 36, of ... completed every year since it started in 2003. This year, he ran all 26.2 ... fellow runners and NBA team the Miami Heat. , This Sunday, while many are ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... ... February 05, 2016 , ... After years as an active staff surgeon ... and cosmetic surgeon Dr. Wayne Carman transitioned to chief of the Division of Plastic ... first three-year term as chief and began a second three-year term in January of ...
(Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... gym use and find themselves having to wait longer to access the treadmills. It’s ... their New Year’s resolutions to lose weight and get in shape by joining gyms, ...
Breaking Medicine News(10 mins):